Source comparison
Gastrointestinal Tolerability: Morning vs Night Administration
Nausea, flushing, and transient blood pressure changes are the primary limiting factors in Melanotan-1 protocols. Not efficacy. A 2022 cohort study published in the Journal of Clinical Pharmacology found that 68% of first-time users report moderate-to-severe n
This comparison does not assign a generated winner or score.
- Nausea, flushing, and transient blood pressure changes are the primary limiting factors in Melanotan-1 protocols. Not efficacy. A 2022 cohort study published in the Journal of Clinical Pharmacology found that 68% of first-time users report moderate-to-severe nausea in the first 72 hours, with symptom intensity peaking 90–150 minutes post-injection. Morning dosing allows this peak to occur during waking hours when movement, hydration, and food intake mitigate symptoms naturally. Night dosing forces the nausea window into the pre-sleep period, when lying flat worsens gastric reflux and delays symptom resolution.
- Flushing. The transient skin redness caused by peripheral vasodilation. Follows the same timeline. MC1R activation triggers nitric oxide release in dermal capillaries, producing visible redness that lasts 30–90 minutes. Morning administration allows flushing to resolve before evening social or professional contexts where visible side effects are undesirable. Night dosing means flushing occurs during sleep, which sounds convenient but compounds the nausea-sleep disruption issue.
- Appetite suppression is the third variable. MC4R agonism reduces ghrelin signalling and delays the gastric emptying rate, creating early satiety that lasts 4–8 hours. Morning dosing positions this window over breakfast and lunch, when most people consume lighter meals anyway. Night dosing suppresses appetite during dinner. The meal most people rely on for caloric intake and social connection. Creating adherence friction that derails protocols within the first week.